ArriVent BioPharma, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Cash Flows

(in thousands)


· · Six Months Ended
· · June 30,
· · 2026 · · 2025
Cash flows from operating activities: · · · ·
Net loss	$(93,213)	$(95,786)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	12,150	5,582
Amortization (accretion) of bond premiums/discounts	(1,074)	—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,008)	(6,346)
Other assets	84	—
Accounts payable	(3,704)	280
Accrued expenses	5,312	2,148
Operating lease liabilities	(20)	(10)
Net cash used in operating activities	(81,473)	(94,132)
Cash flows from investing activities:
Purchase of investments	(78,376)	(31,385)
Sales and maturities of investments	128,030	82,116
Net cash used in investing activities	49,654	50,731
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	139,959	81,857
Proceeds from the exercise of stock options	1,002	369
Payment of deferred financing costs	—	(353)
Net cash provided by financing activities	140,961	81,873

Net increase in cash and cash equivalents	109,142	38,472
Cash and cash equivalents at beginning of the year	45,540	74,293
Cash and cash equivalents at end of the year	$154,682	$112,765

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.